Hints and tips:
Related Special Reports
...It has also worked on drug development for US pharma company Johnson & Johnson, Danish biotech group Genmab and British biotech Iksuda therapeutics....
...Japan’s sovereign development bank is investing in UK life sciences for the first time with funding for 4Bio Capital, a UK venture fund that backs advanced treatments such as cell and gene therapies....
...David Moore, vice-president for corporate development, added that the company would focus on acquisitions in diabetes and obesity, ideally in the early stage of development....
...[Enlarge] Further reading:— Alert: Alphaville LLC issues new research report on Duchy of Cornwall (FTAV)— Greenland: Alphaville put on its sellside hat for the deal of the century (FTAV)— Alphaville LLC...
...Lab monkey prices in China have plummeted as a post-pandemic slowdown in drug development ripples through the pharmaceutical sector in the world’s second-largest economy....
...It has pledged to double funding for dementia research to £160mn a year by 2025....
...Jodie Keane Senior Research Fellow ODI (Formerly Overseas Development Institute), London SE1, UK...
...It has 178 prospects at various stages of development; it has been striking a series of deals, including last month’s $2.4bn agreement to buy Canadian biotech Fusion Pharmaceuticals aimed at bolstering its...
...Susan Galbraith, executive vice-president of oncology research and development at AstraZeneca, said there was an “opportunity to improve” on existing drugs in the area and that the Fusion acquisition would...
...According to a European Commission analysis of the world’s 2,500 highest spending companies in research and development published in 2023, 12 per cent of leading companies investing in health research are...
...Since the third quarter of 2023 when it had 82 new drugs in development, the company has jettisoned 16 drugs and added 12 others, including the weight-loss drug it gained through its $3.1bn acquisition of...
...Developing new antibiotics is often unattractive for pharmaceutical companies, as research and development costs are high but their use is designed to be limited to reduce the risk of the product driving...
...So effective is Vertex Pharmaceuticals’ blockbuster cystic fibrosis (CF) drug, Trikafta, that studies project it could extend the lives of some young patients by up to 45 years....
...Research published this month by the African Private Capital Association (Avca), an industry body, showed there were 450 private capital deals last year in Africa with a combined value of $5.9bn — the biggest...
...Pointing to the risks of unnecessary treatment, Cancer Research UK said over-diagnosis could have “a negative psychological impact”, and treatment of prostate cancer could also cause physical side effects...
...Gathering more than 600 studies in development economics, she found less than 10 per cent mentioned a policy’s costs. (Policymakers care about prices.)...
...This meant a significant proportion of cancer research was only possible because of public donations, she added....
...“They end up being clustered around genes that are altered in cancer in a variety of different ways, providing the first glimpse that these sequences may be key to tumour development,” he said....
...The results from the research, which involved 156 people, were a “major breakthrough”, said Olivier Rascol, a Toulouse University Hospital professor and a co-author of the research with Prof Wassilios Meissner...
...One of his most well-known contributions to research is the ‘Sally-Anne task’....
...Novo Nordisk purchased Dicerna Pharmaceuticals, a company focused in RNA-based therapeutics, for $3.3bn in 2021....
...Johnson’s team have said he had acted as a “diplomatic back channel for the UK”, but the Foreign, Commonwealth and Development Office said he was “not acting on behalf of the UK government”....
...In October, pharmaceuticals companies Eisai and Eli Lilly unveiled research showing the benefits of using new Alzheimer’s drugs very early in the development of the disease....
...Meanwhile, a trial is looking at whether metformin, commonly prescribed for type 2 diabetes, might delay the development of other chronic diseases....
...In contrast, pharmaceutical companies raised just $160mn for antibiotic research, a decline over the decade. Commercial activity and research in antibiotics have been in decline since the 1980s....
International Edition